PROCEPT BioRobotics Securities Fraud Class Action
Analysis based on 6 articles · First reported Aug 21, 2026 · Last updated Aug 28, 2026
The disclosure of the inventory glut and missed revenue guidance caused PROCEPT's stock to drop over 18% in two days, reflecting immediate negative market reaction. The securities class action adds legal and reputational risk, potentially leading to further financial penalties and prolonged uncertainty for the company.
A securities class action lawsuit has been filed against PROCEPT BioRobotics Corporation (NasdaqGM: PRCT) and certain of its executives, alleging they failed to disclose material information during the Class Period from February 28, 2024 to February 25, 2026, in violation of federal securities laws. The lawsuit, Operating Engineers Construction Industry and Miscellaneous Pension Fund v. PROCEPT BioRobotics Corporation, No. 26-cv-07691, is pending in the United States — United States District Court for the Northern District of California. On February 25, 2026, the Company announced its fourth quarter and full year 2025 earnings, disclosing that U.S. handpiece sales had materially exceeded procedures every quarter since Q1 2023, leading to a cumulative excess field inventory of over 10,000 units. Consequently, quarterly handpiece unit sales in the U.S. declined from 13,225 units in Q3 to 9,400 units, a sequential decline of nearly 30%, causing the Company to miss its annual revenue guidance by tens of millions of dollars. Following this news, PROCEPT's share price fell from $27.84 to $22.69 over two days, a decline of over 18%. Kahn Swick & Foti, LLC (KSF) is reminding investors with substantial losses that the deadline to file lead plaintiff applications is September 22, 2026.
Set up alerts, explore entity relationships, search across thousands of events, and build custom intelligence feeds.
Open Dashboard